Pfizer Inc.reports Xalkori lung cancer drug achieves Phase 3 endpoint.
The drug, crizotinib, "significantly improved" progression-free survival when compared with pemetrexed or docetaxel in previously-treated patents with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer, reports added.